Baccine’s first product, Pac-1, was successfully developed and demonstrates strong preclinical evidence of efficacy, substantially improving response and survival in mouse models of cancer.
Pac-1 is a genetically engineered bacterium designed to express and secrete tumor-specific neoantigens and immunomodulator. Its unique multimodal mechanism of action—comprising bacteria-mediated immune activation and tumor targeting, tumor-specific vaccination, and modulation of the tumor microenvironment—contributes to a strong and durable anti-tumor response.